{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:41:40Z","timestamp":1789188100040,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HD107428"],"award-info":[{"award-number":["R01 HD107428"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A simple and reliable HPLC\u2010ultraviolet (HPLC\u2010UV) method was developed and validated for the quantification of pritelivir in the samples of medium from the experiments utilizing the ex vivo technique of dual perfusion of the human placental lobule. Phenacetin was used as an internal standard (IS) in our HPLC\u2010UV method. Chromatographic separation of pritelivir and phenacetin was achieved on a Waters Symmetry C<jats:sub>18<\/jats:sub> HPLC column (100\u2009\u00d7\u20092.1\u2009mm, 3.5\u2009\u03bcm) at ambient temperature (22\u201325\u00b0C). The mobile phase was composed of 50% methanol in deionized water (v\/v), the flow rate for isocratic elution was established at 0.25\u2009mL\/min, and the detection wavelength for pritelivir and IS was set at 254\u2009nm. Pritelivir and IS were extracted with the protein precipitation method using methanol as a solvent. The calibration curve for pritelivir exhibited linearity (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2009&gt;\u20090.99) within the concentration range from 0.155 to 6.62\u2009\u03bcg\/mL. Within\u2010 and between\u2010day accuracy ranged from 97% to 110% with relative standard deviation (RSD) values not exceeding 10%. The extraction recovery of pritelivir and IS ranged from 89% to 91% with RSD not exceeding 7%. Pritelivir was stable under the storage and sample handling conditions. This validated HPLC\u2010UV method was utilized to quantify pritelivir in the placental perfusion medium samples, and the resulting concentrations were authenticated with incurred sample reanalysis to confirm the reliability of the method.<\/jats:p>","DOI":"10.1002\/bmc.5888","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T07:18:53Z","timestamp":1715325533000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of HPLC\u2010ultraviolet method for quantitative determination of pritelivir in human placental perfusion medium"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-568X","authenticated-orcid":false,"given":"Xiaoming","family":"Wang","sequence":"first","affiliation":[{"name":"Maternal\u2010Fetal Pharmacology and Bio\u2010Development Laboratories, Department of Obstetrics &amp; Gynecology University of Texas Medical Branch  Galveston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Patrikeeva","sequence":"additional","affiliation":[{"name":"Maternal\u2010Fetal Pharmacology and Bio\u2010Development Laboratories, Department of Obstetrics &amp; Gynecology University of Texas Medical Branch  Galveston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Nanovskaya","sequence":"additional","affiliation":[{"name":"Maternal\u2010Fetal Pharmacology and Bio\u2010Development Laboratories, Department of Obstetrics &amp; Gynecology University of Texas Medical Branch  Galveston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bryant","sequence":"additional","affiliation":[{"name":"Maternal\u2010Fetal Pharmacology and Bio\u2010Development Laboratories, Department of Obstetrics &amp; Gynecology University of Texas Medical Branch  Galveston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"AiCuris(2020).AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients. [Press Release] June 5 2020.https:\/\/www.aicuris.com\/index.php\/fuseaction\/download\/lrn_file\/200604_aicuris_press-release_pritelivir_fda-break-through.pdf"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1570-0232(02)00244-1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2012.04.044"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02641-14"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1358"},{"key":"e_1_2_8_7_1","unstructured":"FDA. (2018).Guidance for industry bioanalytical method validation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CMV) May 2018.https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.15698\/mic2016.09.528"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1241"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00769-002-0487-6"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2013.05.038"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.06.064"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-092917-043457"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.11.002"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.02.058"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000219749.96274.15"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-7230-7_6"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18189"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.185"},{"key":"e_1_2_8_20_1","unstructured":"World Health Organization. (2008).A review of human carcinogens. Part A: Pharmaceuticals. IARC Working Group on the Evaluation of Carcinogenic Risks to Human (Lyon France).https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK304337\/"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.5888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:37:29Z","timestamp":1760056649000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.5888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/bmc.5888"],"URL":"https:\/\/doi.org\/10.1002\/bmc.5888","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"2024-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5888"}}